Datamonitor, Feb 2011
Introduction
Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as generic erosion of market leaders and increased competition between new
UBM Canon, Nov 2010, Pages: 124
tumours. For instance, a newgeneration of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become blockbuster brands.
Pipelines from the top 15
UBM Canon, June 2010, Pages: 198
approaches to target tumors. For instance, a newgeneration of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become blockbuster brands.
This special
Datamonitor, Nov 2011, Pages: 37
brands in the 2010–2020 period
- Quantify the sales potential late-stage pipeline products
- Assess the impact of key patent expiries, such as Pfizer’s Lipitor (atorvastatin);
- Determine the impact
Spectra Intelligence, Oct 2009, Pages: 81
marketed products to 2016
- Insight and trend analysis of pipeline products for addiction disorders
- Review of promising pipeline products and potential market opportunities
- Extensive coverage of the R
Decision Resources, Inc., March 2011, Pages: 32
. Premium pricing, high sales potential, and rapidly evolving protein-engineering technologies that make biologics even better (biobetters) are driving the industry’s fascination with exploiting new biologics
Decision Resources, Inc., Dec 2009, Pages: 34
the field of oncology and advance the field of personalized medicine. The launch of novel, targeted therapies promises both to offer treatment for previously intractable diseases and to generateblockbuster
Nicholas Hall Group, Oct 2010, Pages: 319
and 2019
- Summary of New Product Development
- Switch pipeline
- Nicholas Hall’s Strategies for Success - Arbidol
- Bai Jia Hei
- Claritin (and Clarinex / Aerius)
- Mucinex
- Otrivin
- Strepsils
UBM Canon, Sep 2011, Pages: 234
promising product pipeline belongs to Novartis, which generated a 14% net sales increase and received 13 major regulatory approvals in 2010.
The company's principal goal is to discover new medicines
Spectra Intelligence, Nov 2011, Pages: 66
products with limited market potential thus offering a poor fit for companies based upon the blockbuster model. However, a number of major companies have reassessed their strategy with respect to orphan
Decision Resources, Inc., Dec 2008, Days: 65
that has centered for years on the fully integrated pharma company (FIPCO) and the blockbuster drug. Is there an imperative for a shift in pharmaceutical business models? Does adopting a new approach
GBI Research, Aug 2010, Pages: 125
markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic
Business Insights, Feb 2005, Pages: 132
The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital, as a result competitive pressures and falling
GBI Research, Dec 2009, Pages: 132
into the monoclonal antibodies R&D pipeline and the potentialblockbusters.
The report also elucidates monoclonal antibodies competitive landscape including benchmarking of leading companies. Finally, key trend
UBM Canon, Feb 2011, Pages: 68
continues to garner the attention of R&D managers and other industry executives. Accordingly, potentialnewblockbuster drugs are expected to penetrate the market including Remoxy, an oxycodone drug
GBI Research, March 2011
provided in the report. The report includes insights into the antifungals R&D pipeline and potential future blockbusters up to 2016.
The report provides an in-depth analysis of the top three antifungals
Datamonitor, Oct 2010, Pages: 196
franchise provides blockbuster vaccine sales for Pfizer
Weaknesses: strong reliance on Prevnar franchise as sole revenue generator
Opportunities: expansion into new geographies and target groups
GBI Research, June 2011, Pages: 77
and analysis of the major trends and developments in the drug devleopment business. The report provides a comprehensive insight into key technological developments, new approaches in lead generation and various
Frost & Sullivan, Dec 2008, Pages: 88
, and drive effective strategies for growth. For more information on this custom subscription service, please click here.
Market Overview
Niche Blockbusters Offer Promising Growth Potential
The patent expiry
GBI Research, Sep 2011, Pages: 142
. The report also includes details about therapeutic proteins R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of the main therapeutic protein classes, which
